CTMX Q2 2018 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$822M

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$21M+143.8% YoY

Gross Profit

$21M100.0% margin

Operating Income

-$13M-62.1% margin

Net Income

-$13M-63.0% margin

EPS (Diluted)

$-0.35

QoQ Revenue Growth

+50.4%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$27M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$377M

Total Liabilities

$336M

Stockholders' Equity

$41M

Cash & Equivalents

$133M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$21M	$9M	+143.8%
Gross Profit	$21M	$9M	+143.8%
Operating Income	-$13M	-$25M	+47.8%
Net Income	-$13M	-$25M	+46.7%

Revenue Segments

E G F R Products

$42M91%

Amgen Other Products

$4M9%